These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31526534)

  • 21. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses.
    Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK
    JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Could ingenol mebutate be useful in managing nonmelanoma skin cancers?
    Bhandari PR; Pai VV
    Indian J Cancer; 2015; 52(2):249-50. PubMed ID: 26853424
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas.
    Bucko AD; Jarratt M; Stough DB; Kyhl L; Villumsen J; Hall A
    J Dermatolog Treat; 2018 Feb; 29(1):74-79. PubMed ID: 28524709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
    Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Goncalves J; Larsson T; Skov T; Swanson N
    J Drugs Dermatol; 2014 Feb; 13(2):154-60. PubMed ID: 24509965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ingenol Mebutate 500 µg on the Cheekbones with Concomitant Conjunctivitis.
    Gaide O; Cattin V
    Dermatology; 2016; 232 Suppl 1():4-6. PubMed ID: 27513756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
    Stockfleth E; Bastian M
    Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face.
    Jim On SC; Hashim PW; Nia JK; Lebwohl MG
    J Drugs Dermatol; 2017 May; 16(5):432-436. PubMed ID: 28628678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ingenol mebutate: an introduction.
    Fallen RS; Gooderham M
    Skin Therapy Lett; 2012 Feb; 17(2):1-3. PubMed ID: 22358305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ingenol Mebutate as Treatment of Squamous Cell Carcinoma In Situ: A Case Series.
    Khalfe Y; Rosen T
    J Drugs Dermatol; 2021 Feb; 20(2):169-171. PubMed ID: 33538561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ingenol mebutate: a new option for actinic keratosis treatment.
    Gras J
    Drugs Today (Barc); 2013 Jan; 49(1):15-22. PubMed ID: 23362492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
    Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
    Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Actinic keratosis].
    Heppt MV; Steeb T; Szeimies RM; Berking C
    Hautarzt; 2020 Aug; 71(8):588-596. PubMed ID: 32468291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
    Jedlowski PM
    J Cutan Med Surg; 2023; 27(1):39-43. PubMed ID: 36495205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erosive pustular dermatosis of the scalp induced by ingenol mebutate.
    Brambilla L; Tourlaki A; Nazzaro G
    G Ital Dermatol Venereol; 2018 Oct; 153(5):743-745. PubMed ID: 28895376
    [No Abstract]   [Full Text] [Related]  

  • 35. Quantifying Actinic Keratosis Transformation Using a Risk Analysis Calculator.
    Ravishankar A; Maher IA; Gravely AA; Goldfarb NI
    Dermatol Surg; 2021 Jan; 47(1):141-144. PubMed ID: 31634255
    [No Abstract]   [Full Text] [Related]  

  • 36. A multicentre, open, investigator-initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0·015% on the face and scalp, and 0·05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT).
    Kim YC; Yang JY; Yoon JS; Jo SJ; Ahn HH; Song KH; Lee DY; Chung KY; Won YH; Kim IH
    Br J Dermatol; 2018 Oct; 179(4):836-843. PubMed ID: 29355904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results.
    Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Larsson T; Swanson N
    J Drugs Dermatol; 2014 Jun; 13(6):741-7. PubMed ID: 24918567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of local skin reactions after the application of ingenol mebutate gel for the treatment of actinic keratosis: four illustrative cases.
    Longo C; Neri L; Argenziano G; Calvieri S; Calzavara-Pinton PG; Cantisani C; Catricalà C; Peris K; Peserico A; Pimpinelli N; Pellacani G
    J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):320-1. PubMed ID: 25186255
    [No Abstract]   [Full Text] [Related]  

  • 39. Full face ingenol mebutate for actinic keratosis: patient perspective.
    Anthony E; Lun K; Smith SD
    Int J Dermatol; 2019 Jan; 58(1):e6-e9. PubMed ID: 30302750
    [No Abstract]   [Full Text] [Related]  

  • 40. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
    Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
    Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.